

Response rates and durability of chemotherapy among cell carcinoma

Cancer Medicine

5, 2294-2301

DOI: [10.1002/cam4.815](https://doi.org/10.1002/cam4.815)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	10.7	1,034
2	Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2016, 5, 2294-2301.	2.8	203
3	Embracing a Standard of Care for Merkel Cell Carcinoma With Immunotherapy. <i>Clinical Skin Cancer</i> , 2016, 1, 53-56.	0.1	0
4	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1658-1666.	1.2	26
5	New developments in the biology and the treatment of metastatic Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2017, 29, 221-226.	2.4	42
6	Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2509-2530.	4.7	151
7	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. <i>Future Oncology</i> , 2017, 13, 1699-1710.	2.4	98
8	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	2.4	113
9	Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. <i>Cancer</i> , 2017, 123, 1464-1474.	4.1	132
10	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	2.8	307
11	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17077.	30.5	393
12	Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2157-2162.	1.0	12
13	Advances in Merkel cell carcinoma from a pathologist's perspective. <i>Pathology</i> , 2017, 49, 568-574.	0.6	16
14	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncoimmunology</i> , 2017, 6, e1338237.	4.6	47
15	Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 969-973.	0.8	3
18	Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4803-4807.	2.0	14
20	Biopsy-Proven Metastatic Merkel Cell Carcinoma to the Orbit: Case Report and Review of Literature. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e86-e88.	0.8	8
21	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 345-359.	3.1	27

#	ARTICLE	IF	CITATIONS
22	Avelumab: a new standard for treating metastatic Merkel cell carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 319-326.	2.4	23
23	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	3.7	30
24	Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. Annals of Pharmacotherapy, 2018, 52, 928-935.	1.9	10
25	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncology, 2018, 14, 255-266.	2.4	22
26	Merkel cell carcinoma: An update and review. Journal of the American Academy of Dermatology, 2018, 78, 445-454.	1.2	90
27	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
28	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. JAMA Oncology, 2018, 4, e180077.	7.1	304
29	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2018, 24, 2035-2043.	7.0	75
30	Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America. Journal of Global Oncology, 2018, 4, 1-11.	0.5	5
32	Immunotherapy for Merkel Cell Carcinoma. Current Treatment Options in Oncology, 2018, 19, 57.	3.0	12
33	Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone,) Tj ETQq0 0 0 rgBT /Overlock 10 Hematopathology: JCEH, 2018, 58, 184-187.	0.8	4
34	Radiation Therapy in Merkel Cell Carcinoma. , 2018, , 1-20.		1
35	Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness. PLoS Pathogens, 2018, 14, e1007276.	4.7	24
36	Avelumab: A Review in Metastatic Merkel Cell Carcinoma. Targeted Oncology, 2018, 13, 409-416.	3.6	27
37	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Journal of Pain and Symptom Management, 2018, 56, 460-472.	1.2	14
38	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology, 2018, 13, 567-582.	3.6	12
39	How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet Journal of Rare Diseases, 2018, 13, 95.	2.7	13
40	Merkel Cell Carcinoma: An Update and Immunotherapy. Frontiers in Oncology, 2018, 8, 48.	2.8	40

#	ARTICLE	IF	CITATIONS
41	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
42	Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States. Journal of Medical Economics, 2018, 21, 1159-1171.	2.1	4
43	Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research. Future Oncology, 2018, 14, 2841-2848.	2.4	17
44	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	4.9	202
45	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	7.0	97
47	Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma. Case Reports in Oncology, 2019, 12, 639-643.	0.7	10
49	Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report. Oral Oncology, 2019, 99, 104350.	1.5	6
50	Cells to Surgery Quiz: August 2019. Journal of Investigative Dermatology, 2019, 139, e91-e97.	0.7	0
51	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. Value in Health, 2019, 22, 1170-1177.	0.3	2
52	Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma. JAAD Case Reports, 2019, 5, 849-851.	0.8	15
53	Monoclonal Antibodies in Dermatooncology – State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	3.7	9
54	Merkel Cell Carcinoma – Current Controversies and Future Directions. Clinical Oncology, 2019, 31, 789-796.	1.4	15
55	Management of regional metastatic disease in cutaneous malignancy of the head and neck. 3. Merkel cell carcinoma. British Journal of Oral and Maxillofacial Surgery, 2019, 57, 847-856.	0.8	4
56	Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know. Radiographics, 2019, 39, 2069-2084.	3.3	21
57	Updates on Merkel Cell Carcinoma. Dermatologic Clinics, 2019, 37, 489-503.	1.7	23
58	The impact of facility characteristics on Merkel cell carcinoma outcomes: A retrospective cohort study. Journal of the American Academy of Dermatology, 2023, 89, 70-80.	1.2	10
59	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. Pharmacoeconomics - Open, 2019, 3, 377-390.	1.8	20
62	Merkel Cell Carcinoma. Dermatologic Clinics, 2019, 37, 269-277.	1.7	41

#	ARTICLE	IF	CITATIONS
63	Mitochondria-Targeted and Resveratrol-Loaded Dual-Function Titanium Disulfide Nanosheets for Photothermal-Triggered Tumor Chemotherapy. <i>Nanoscale Research Letters</i> , 2019, 14, 211.	5.7	27
64	S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) â€“ Update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 562-577.	0.8	13
65	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. , 2019, 7, 141.		14
66	<p>Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 349-359.	1.9	4
67	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) â€“ update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 562-576.	0.8	27
68	Travel burden associated with rare cancers: The example of Merkel cell carcinoma. <i>Cancer Medicine</i> , 2019, 8, 2580-2586.	2.8	18
69	Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab. <i>Frontiers in Oncology</i> , 2019, 9, 223.	2.8	21
70	Immunotherapy in non-melanoma skin cancer: updates and new perspectives. <i>Drugs in Context</i> , 2019, 8, 1-6.	2.2	6
71	Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. , 2019, 23, E1-E9.		3
72	Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. <i>JAMA Dermatology</i> , 2019, 155, 803.	4.1	21
73	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274
74	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	4.2	21
75	Inâ€“transit recurrence of Merkel cell carcinoma associated with Bowen's disease: The first reported case successfully treated by avelumab. <i>Journal of Dermatology</i> , 2019, 46, 440-443.	1.2	0
76	Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. <i>Dermatology and Therapy</i> , 2019, 9, 209-222.	3.0	54
77	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 391-407.	6.7	35
78	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	3.7	22
79	Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvals. <i>Future Oncology</i> , 2019, 15, 4057-4067.	2.4	3
80	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019, 4, 1-7.	0.3	2

#	ARTICLE	IF	CITATIONS
81	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	7.0	118
82	Immune Checkpoints. , 2019, , 19-43.		0
83	Merkel Cell Carcinoma Review. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 39-52.	2.2	39
84	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	3.3	50
85	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	2.5	13
86	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. <i>Cancer Medicine</i> , 2020, 9, 1374-1382.	2.8	52
87	Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. , 2020, 8, e001076.		18
88	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
89	Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1093-1106.	2.4	4
90	Case of Merkel cell carcinoma in a patient with pre-existing ILD. , 2020, 8, e001672.		1
91	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	1.1	13
92	Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. <i>Future Oncology</i> , 2020, 16, 2521-2536.	2.4	4
93	Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative 1 st exon 6â€“7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8222.	4.1	4
94	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
95	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
96	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 810-817.	3.7	11
97	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. <i>BMC Medical Research Methodology</i> , 2020, 20, 103.	3.1	10
98	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	2.7	11

#	ARTICLE	IF	CITATIONS
99	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 398-407.	3.8	29
101	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective. Cancers, 2020, 12, 554.	3.7	15
102	Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma. International Ophthalmology Clinics, 2020, 60, 91-102.	0.7	6
103	Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity. Biology, 2020, 9, 35.	2.8	11
104	Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities. Acta Oncologica, 2020, 59, 793-796.	1.8	6
105	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology, 2020, 38, 2476-2487.	1.6	152
106	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. British Journal of Dermatology, 2021, 184, 319-327.	1.5	28
107	Current concepts and approaches to merkel cell carcinoma. Archives of Dermatological Research, 2021, 313, 129-138.	1.9	7
108	Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncology, 2021, 17, 333-347.	2.4	13
109	Molecular Pathogenesis of Merkel Cell Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 69-91.	22.4	59
110	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Human Vaccines and Immunotherapeutics, 2021, 17, 1935-1939.	3.3	8
111	Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations. Cancer Immunology, Immunotherapy, 2021, 70, 1031-1036.	4.2	3
113	Review of Merkel cell carcinoma – what is known and unknown. Oncolog-Hematolog Ro, 2021, 2, 20.	0.0	0
114	Nomogram prediction for the overall survival and cancer-specific survival of patients diagnosed with Merkel cell carcinoma. Annals of Translational Medicine, 2021, 9, 286-286.	1.7	5
115	Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 213-226.	1.9	1
116	Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma. Frontiers in Oncology, 2021, 11, 625360.	2.8	3
118	Treating neuroendocrine neoplasms in the setting of HIV infection. Translational Science of Rare Diseases, 2021, 5, 143-159.	1.5	1
119	Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, 87, 121-130.	1.2	7

#	ARTICLE	IF	CITATIONS
120	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
121	How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncology, 2021, 17, 1363-1377.	2.4	23
122	Merkel Cell Polyomavirus Infection Induces an Antiviral Innate Immune Response in Human Dermal Fibroblasts. Journal of Virology, 2021, 95, e0221120.	3.4	17
123	Real-world clinical outcomes with first-lineÂavelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Future Oncology, 2021, 17, 2339-2350.	2.4	9
124	RF- Immunotherapy in Merkel Cell Carcinoma. Actas Dermo-sifiliogrÃjficas, 2021, 112, 553-555.	0.4	0
125	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	3.7	15
126	Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma. Melanoma Research, 2021, 31, 421-425.	1.2	2
127	<scp>Real-World</scp>Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from<scp>SPEAR-Merkel</scp>. Oncologist, 2021, 26, e1633-e1643.	3.7	4
128	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq0 0 0 rgBT /Overlock 10 T		52
129	An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. Cancer Medicine, 2021, 10, 5889-5896.	2.8	10
130	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. International Journal of Molecular Sciences, 2021, 22, 8679.	4.1	3
131	Successful rechallenge with avelumab in Merkel cell carcinoma. European Journal of Cancer, 2021, 153, 96-97.	2.8	2
132	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. Frontiers in Oncology, 2021, 11, 739006.	2.8	12
133	The Association of Radiation Therapy and Chemotherapy on Overall Survival in Merkel Cell Carcinoma: A Population-Based Analysis. Cureus, 2021, 13, e18276.	0.5	1
134	From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis. Frontiers in Microbiology, 2021, 12, 739695.	3.5	29
136	Cutaneous Malignancies of the Head and Neck. Hematology/Oncology Clinics of North America, 2021, 35, 991-1008.	2.2	0
137	Ubiquitous Merkel Cell Polyomavirus: Causative Agent of the Rare Merkel Cell Carcinoma. , 2021, , 353-383.		0
138	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs, 2020, 34, 495-503.	4.6	15

#	ARTICLE	IF	CITATIONS
139	Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth <i>in vitro</i> . Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097562.	3.2	9
140	Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. American Journal of Case Reports, 2018, 19, 505-511.	0.8	29
141	Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma. International Journal of Particle Therapy, 2017, 3, 485-491.	1.8	7
142	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. International Journal of Particle Therapy, 2018, 5, 183-195.	1.8	15
143	LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma. EMBO Molecular Medicine, 2020, 12, e12525.	6.9	41
144	Understanding the influence of patient demographics on disease severity, treatment strategy, and survival outcomes in merkel cell carcinoma: a surveillance, epidemiology, and end-results study. Oncoscience, 2017, 4, 106-114.	2.2	20
145	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget, 2017, 8, 79731-79741.	1.8	77
146	Effectiveness of Combined Anti-programmed Death-ligand 1 Therapy and Radiotherapy for Metastatic Merkel Cell Carcinoma: Two Case Reports. Acta Dermato-Venereologica, 2020, 100, adv00237.	1.3	1
147	Cutaneous Melanoma and Other Skin Cancers. UNIPA Springer Series, 2021, , 979-1007.	0.1	0
148	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. Journal of Dermatological Science, 2022, 105, 2-10.	1.9	10
149	Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after 5 years of follow-up. ESMO Open, 2021, 6, 100290.	4.5	28
150	Carcinome de Merkel : actualités physiopathologiques et thérapeutiques. Oncologie, 2018, 20, 19-26.	0.7	1
152	Avelumab in the treatment of patients with merkel cell carcinoma: initial results of early access program in Russia. Malignant Tumours, 2019, 9, 53-58.	0.5	1
153	Palliative Systemic Treatment of Advanced Merkel Cell Carcinoma in the Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis of Patients with An Orphan Neuroendocrine Malignancy. Oncogen, 2019, 2, .	0.3	0
155	Avelumab, una nueva inmunoterapia para pacientes con carcinoma de células de Merkel metastásico. Piel, 2019, 34, 518-519.	0.0	0
156	Avelumab for the treatment of patients with Merkel cell carcinoma. Meditsinskiy Sovet, 2020, , 94-100.	0.5	0
158	Merkel cell carcinoma in Turkey: A multicentric study. Journal of Cancer Research and Therapeutics, 2021, 17, 1525.	0.9	0
159	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0

#	ARTICLE	IF	CITATIONS
160	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2017, 10, S8-S41.	0.1	2
161	Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options. Dermatologic Therapy, 2022, 35, e15292.	1.7	20
162	Merkel cell polyomavirus and associated Merkel cell carcinoma. Tumour Virus Research, 2022, 13, 200232.	3.8	12
163	Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. Clinical Cancer Research, 2022, 28, 2211-2220.	7.0	23
164	Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma. Oxford Medical Case Reports, 2022, 2022, omac012.	0.4	1
165	The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma. Frontiers in Oncology, 2022, 12, 832047.	2.8	30
166	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. Frontiers in Oncology, 2021, 11, 734354.	2.8	17
168	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline “Update 2022. European Journal of Cancer, 2022, 171, 203-231.	2.8	51
169	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. JCI Insight, 2022, 7, .	5.0	5
170	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. , 2022, 10, e004434.		14
171	A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma. Journal of Immunotherapy, 2022, 45, 299-302.	2.4	13
174	Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update. Molecular Carcinogenesis, 2023, 62, 101-112.	2.7	4
175	Merkel Cell Polyomavirus (MCPyV) and Cancers: Emergency Bell or False Alarm?. Cancers, 2022, 14, 5548.	3.7	3
177	Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case“Control Study and Literature Review. Cancers, 2022, 14, 5914.	3.7	2
178	The Current Management of Merkel Carcinoma of the Head and Neck: a Scoping Review. SN Comprehensive Clinical Medicine, 2023, 5, .	0.6	0
179	Current treatments and emerging therapies of human polyomavirus-associated skin diseases: a comprehensive review. International Journal of Dermatology, 2023, 62, 387-396.	1.0	5
181	Merkel cell carcinoma: an update. Human Pathology, 2023, 140, 39-52.	2.0	4
182	S2k Guideline “Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) “Update 2022. JDDG - Journal of the German Society of Dermatology, 2023, 21, 305-320.	0.8	3

#	ARTICLE	IF	CITATIONS
183	S2kâ€Leitlinie â€“ Merkelzellkarzinom â€“ Update 2022. JDDG - Journal of the German Society of Dermatology, 2023, 21, 305-317.	0.8	1
184	Characterization of the Impact of Merkel Cell Polyomavirus-Induced Interferon Signaling on Viral Infection. Journal of Virology, 2023, 97, .	3.4	2
186	ä,â”†â€ç™ç”Ÿä—äŸäfjâf«â,±âf«ç”èfžç™Œä@1ä¾. Nihon Koku Geka Gakkai Zasshi, 2023, 69, 48-52.	0.0	0
187	Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?. Journal of Personalized Medicine, 2023, 13, 841.	2.5	0
188	Merkel cell carcinoma: a review of clinical management with focus on Asian patients. Japanese Journal of Clinical Oncology, 2023, 53, 673-679.	1.3	1
189	Applications Using Real-World Evidence to Accelerate Medical Product Development. , 2023, , 365-386.		0
191	Review of Merkel cell carcinoma with solitary pancreatic metastases mimicking primary neuroendocrine tumor of the pancreas. Clinical Journal of Gastroenterology, 0, , .	0.8	0
193	An Investigation of Structureâ€Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells. Marine Drugs, 2023, 21, 474.	4.6	1
194	Characterization of molecular mechanisms driving Merkel cell polyomavirus oncogene transcription and tumorigenic potential. PLoS Pathogens, 2023, 19, e1011598.	4.7	1
195	Epigenetic germline variants predict cancer prognosis and risk and distribute uniquely in topologically associating domains. F1000Research, 0, 12, 1083.	1.6	0
196	Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review. Orbit, 0, , 1-18.	0.8	0
197	Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature. Endocrine, 0, , .	2.3	0
199	Longitudinal multi-functional analysis identified responses of T cells, B cells, and monocytes as hallmarks of immunotherapy tolerance in patients with merkel cell carcinoma. PLoS ONE, 2023, 18, e0293922.	2.5	0
201	The Evaluation and Treatment of Merkel Cell Carcinoma and Brain Metastasis: A Case Report and Review of the Literature. Cureus, 2023, , .	0.5	0
202	An Overview of Advances in Rare Cancer Diagnosis and Treatment. International Journal of Molecular Sciences, 2024, 25, 1201.	4.1	0
203	Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review. Dermatologic Surgery, 2024, 50, 407-411.	0.8	0